Written by Dr. Haroun Gajraj, GMC-registered Vascular Specialist, Founder & Board Member of the British Association of Sclerotherapists (BAS).

Last updated: 29th July 2026.

Target Audience: Healthcare professionals treating leg telangiectasias and reticular veins using microsclerotherapy.

Series Context: This is Part 2 of a two-part evidence-based review. Part 1 covers topical agents and chelation therapy for established hyperpigmentation.

This review is written for healthcare professionals treating leg telangiectasias and reticular veins by Microsclerotherapy. Part 1 of this series looked at topical agents for established post-sclerotherapy pigmentation (PSP) and was honest about the limits of that evidence. This article covers the other side of the picture: why PSP happens, how to reduce the risk of it happening at all, and the full staged approach to managing it when it does.

This is Part 2 of a two-part series. Topical agents are covered in detail in our [evidence review of topical agents for post-sclerotherapy pigmentation]

TL;DR for Busy Clinicians

• PSP incidence ranges from under 3% with polidocanol 0.25% to nearly 73% with polidocanol 1.0%. Concentration is the single most controllable variable.

• PSP presents in two patterns: linear staining (follows the vessel, more preventable) and diffuse staining (broader, more likely to persist, usually a sign the sclerosant was too strong or too much was given at one site).

• Six prevention strategies matter most: correct concentration, treating reticular feeders before spider vein clusters, early coagulum evacuation, adequate graduated compression, strict sun protection, and pharmacological adjuncts in higher-risk patients.

• Sulodexide has genuine randomised trial evidence (14.8% to 8.7% incidence, P = 0.01). Micronized purified flavonoid fraction (MPFF) has supportive observational evidence, not randomised trial evidence, and the two should not be graded the same way.

• Established PSP is managed on a staged timeline: reassurance and compression in the first six weeks, topical agents from six weeks, deferoxamine mesylate or the triple combination cream from six to twelve months, and energy-based devices for anything resistant beyond twelve months. Topical agents and deferoxamine are covered in detail in Part 1.

• If PSP persists or worsens beyond six months, reassess for a patent reticular feeder vein or truncal reflux before adding more topical or device-based therapy.

🎥 Prefer video? Watch the full review on YouTube: "Post-Sclerotherapy Staining and Pigmentation: Evidence-Based Prevention & Staged Management Guide" [ click here ]

Contents

Introduction

PSP Incidence: Why the Numbers Vary So Widely

The Two Clinical Patterns of PSP

Patient-Related and Procedure-Related Risk Factors

Six Strategies to Prevent PSP

The Full Staged Management Algorithm

When to Reassess for Venous Reflux

Key Clinical Points

Frequently Asked Questions

References

Introduction

Post-sclerotherapy pigmentation is the most commonly reported cosmetically significant adverse sequela of Microsclerotherapy. In Part 1, we looked honestly at the evidence, or lack of it, for topical treatment of PSP once it has developed. This article takes a step back. Most PSP is preventable, and the practitioner has more control over its occurrence than is often appreciated.

PSP Incidence: Why the Numbers Vary So Widely

The commonly cited range of 10 to 30% of patients affected short-term comes from Goldman's landmark 1995 paper, which established the benchmark for telangiectasia and reticular vein treatment across vessels of 0.1 to 5 mm diameter treated with polidocanol [1].

A systematic review by Bossart and colleagues examined concentration-specific data for polidocanol and reported incidence ranging from 2 to 12% using polidocanol 0.25%, 12.5 to 67.9% using polidocanol 0.5%, and 13 to 73% using polidocanol 1.0% [2]. That range, from under 3% to nearly three in four patients, is almost entirely explained by sclerosant concentration, which is the single most controllable variable available to the practitioner. The same review confirmed that foam sclerotherapy consistently produces higher PSP rates than liquid at equivalent concentrations [2].

The natural history is reassuring. Goldman and colleagues reported that 80% of patients with PSP clear spontaneously within 6 to 24 months, with a small number retaining pigmentation for up to 5 years [3]. Approximately 70% of cases resolve by 6 months, and persistent pigmentation beyond 12 months affects a small minority, estimated at 1 to 2% in clinical practice [1].

The Two Clinical Patterns of PSP

Recognising which pattern is present provides immediate insight into the underlying cause and guides management.

Linear staining follows the precise anatomical course of the treated vessel, presenting as a dark brown line where the spider vein used to be. It is caused by degradation of intraluminal thrombus. As the coagulum breaks down, haemosiderin is released and deposits along the vessel lumen [3][4]. This is the most common pattern after Microsclerotherapy of telangiectasias and small reticular veins, and it is the more preventable of the two patterns. Early evacuation of intraluminal coagulum at the one to two week review significantly reduces its incidence [4].

Diffuse staining produces a broader, cloud-like or coin-shaped area of discolouration that does not follow the vessel course. It results from vessel wall disruption, typically caused by excessive sclerosant concentration or volume, leading to widespread extravasation of red cells into the surrounding reticular dermis [1][2]. This pattern is more extensive, more cosmetically distressing, and more likely to persist. Its presence almost invariably indicates that the sclerosant was too concentrated, or too much was injected at a single site.

Patient-Related and Procedure-Related Risk Factors

Patient-related risk factors:

• Darker Fitzpatrick skin types (III to VI): melanocytes are more reactive to inflammatory stimuli, increasing the post-inflammatory melanin component of PSP [1][2].

• Elevated serum ferritin or high body iron stores: a linear relationship between pre-treatment serum ferritin and PSP occurrence has been demonstrated in prospective studies [10], although its clinical utility as a predictor remains debated, since a subsequent analysis found this relationship was not always consistent [11].

• Oestrogen, whether from the oral contraceptive pill or hormone replacement therapy, has a demonstrated effect on melanocyte biology, although the laboratory evidence is more complex than a simple stimulatory effect: in vitro work found that oestradiol increased melanocyte proliferation while actually decreasing melanin content and tyrosinase activity [12]. Oestrogen exposure is also thought to increase capillary fragility.

• Superficial telangiectasia: haemosiderin deposits in the reticular dermis are more visible through thin overlying skin in telangiectasia territory [1][3].

• Sensitive or reactive skin: an amplified histamine response increases local inflammatory activity and endothelial cell contraction, allowing extravasation of red blood cells.

Procedure-related risk factors:

• High sclerosant concentration is the single most important and modifiable risk factor, with incidence rising from under 12% with polidocanol 0.25% to up to 73% with polidocanol 1.0% [1][2].

• Foam sclerotherapy acts as a more potent sclerosant than liquid at equivalent concentration, with multiple studies confirming higher pigmentation rates for foam [2][9].

• Perivascular extravasation of sclerosant, due to incorrect needle placement or excessive injection pressure, allows red blood cells to leak outside the vessel [1].

• A large intraluminal coagulum leaves more haemosiderin substrate for degradation. Evacuation of the coagulum at 1 to 2 weeks significantly reduces this risk [4].

• Inadequate post-treatment compression allows blood to re-enter the sclerosed lumen, increasing thrombus burden [5].

• UV sun exposure in the peri-treatment period stimulates melanocytes in already-inflamed skin, amplifying the melanin component [1][3].

Six Strategies to Prevent PSP

Strategy 1: use the correct sclerosant concentration. Use the lowest effective concentration of liquid sclerosant. For telangiectasias and small reticular veins, liquid polidocanol at 0.5% or lower, or liquid sodium tetradecyl sulphate at 0.2% or lower, represent appropriate starting concentrations [1][2]. If using foam for C1 disease, the increased potency means concentrations should be reduced further [9].

Strategy 2: treat reticular veins before spider vein clusters. Treating larger reticular feeder veins before addressing the smaller telangiectatic clusters they supply reduces intraluminal filling pressure and the tendency for blood to re-enter treated vessels, limiting thrombus volume and haemosiderin load [1][3].

Strategy 3: evacuate the coagulum early. At the one to two week post-treatment review, examine all treated areas for regions that are bulging, tender, or beginning to darken. A simple nick with a 19 to 21 gauge needle, followed by gentle expression of the retained blood, dramatically reduces the haemosiderin burden and the risk of linear staining [4]. Scultetus and colleagues demonstrated that microthrombectomy significantly reduced PSP rates for veins of 1 mm or smaller [4].

Strategy 4: prescribe adequate graduated compression. Graduated compression reduces the residual vein lumen, promotes apposition of vessel walls, limits the volume of blood available for thrombus formation, and reduces local hydrostatic pressure. Kern and colleagues demonstrated in a randomised controlled study that compression significantly reduced PSP after sclerotherapy of telangiectasias and reticular leg veins [5]. Nootheti and colleagues showed that an additional three weeks of Class I compression, 20 to 30 mmHg, beyond the immediate post-treatment period further reduced pigmentation rates [6].

Strategy 5: advise strict sun protection. Patients should avoid direct UV exposure to treated areas for a minimum of 2 to 4 weeks after treatment and apply broad-spectrum sunscreen, SPF 30 to 50 or higher, when outdoors [1][3]. This is a zero-cost intervention that is frequently omitted from aftercare instructions.

Strategy 6: consider pharmacological adjuncts in higher-risk patients. Two venoactive agents have been studied as adjuncts to sclerotherapy for PSP prevention, and it is worth being precise about the evidence tier for each.

Sulodexide is a highly purified mixture of the glycosaminoglycans heparin and dermatan sulfate. In a randomised controlled trial of 720 enrolled patients, of whom 609 completed the three-month follow-up, oral sulodexide taken for one week before and three months after sclerotherapy reduced PSP incidence from 14.8% to 8.7% at one month (P = 0.01), without affecting clinical vein clearance outcomes [7]. This is genuine randomised trial evidence. Sulodexide is licensed in some countries in Europe, the Middle East, and South America, but is not available in many territories, including the UK.

Micronized purified flavonoid fraction (MPFF) was studied in the VEIN ACT PROLONGED-C1 programme, a national, multicentre observational programme involving over 1,100 patients, in which MPFF 1000 mg per day, commenced two weeks before and continued six weeks after sclerotherapy, was associated with a reduction in PSP rates from 41.2% to 33.9% (P = 0.034) [8]. It is important to be clear that this is observational, not randomised, evidence. It is a reasonable and interesting signal, but it sits on a different evidence tier from the sulodexide trial, and the two should not be described interchangeably.

The Full Staged Management Algorithm

For established PSP, treatment should be guided by the dominant pigment, by how long the pigmentation has been present, and by response to earlier steps. The following algorithm reflects current evidence and expert consensus.

Time Stage Situation Management 0 to 6 weeks All PSP Reassurance. Strict sun protection (SPF 30-50+). Graduated compression (20-30 mmHg). Coagulum evacuation at 1 to 2 week review if bulging or tender. 6 weeks to 6 months Persistent PSP Continue sun protection and compression. Add topical depigmenting agents, covered in detail in Part 1 of this series. 6 to 12 months Persistent PSP Triple combination cream (see Part 1). Consider deferoxamine mesylate, subcutaneous or intradermal, off-label (see Part 1). Laser or IPL evaluation. Beyond 12 months Resistant PSP Q-switched Nd:YAG laser with or without IPL. Deferoxamine mesotherapy (see Part 1). Combined laser modalities. Identify the dominant pigment before selecting a modality.

A note on energy-based devices, which sit at the far end of this algorithm and are mentioned here for completeness rather than covered in depth. Energy-based devices are generally reserved for PSP that has not responded to topical or chelation treatments. Q-switched Nd:YAG laser at 1064 nm causes selective photoacoustic fragmentation of both haemosiderin and melanin granules, which macrophages then transport away via the lymphatics. Small case series and reviews report meaningful reduction in pigmentation with this approach. Intense pulsed light, with or without radiofrequency, has also been reported to achieve complete regression in the majority of treated patients in small studies, with ultrasound-confirmed normalisation of dermal echogenicity [13]. Combined laser approaches, such as Nd:YAG plus Er:YAG plus IPL, have been documented in case reports for complex or mixed-pigment presentations [14]. As with several of the topical agents discussed in Part 1, much of this evidence comes from small case series rather than randomised trials, and should be read accordingly.

When to Reassess for Venous Reflux

An important clinical caveat: if PSP persists beyond 6 months, or is worsening rather than improving, the treating clinician should reassess for a patent reticular feeder vein or persistent superficial truncal or tributary venous reflux [2][3]. Ongoing venous hypertension perpetuates extravasation of red cells and continued haemosiderin deposition. Treating the underlying reflux is an essential step before, or concurrent with, topical or device-based therapies in these cases.

Key Clinical Points

• PSP incidence is most powerfully determined by sclerosant concentration, ranging from under 3% with polidocanol 0.25% to nearly 73% with polidocanol 1.0%.

• Linear staining is the more common and more preventable pattern. Diffuse staining usually indicates excessive concentration or volume at a single site.

• Darker Fitzpatrick skin types, elevated ferritin, oestrogen exposure, and superficial telangiectasia territory are the main patient-related risk factors.

• Six prevention strategies matter most: correct concentration, treating feeders before clusters, early coagulum evacuation, adequate compression, sun protection, and pharmacological adjuncts in higher-risk patients.

• Sulodexide has randomised trial evidence for PSP prevention. MPFF has observational evidence only, and the two evidence tiers should not be conflated.

• The staged management algorithm runs from reassurance and compression in the first six weeks, through topical agents and deferoxamine mesylate (both covered in Part 1), to energy-based devices for resistant cases beyond twelve months.

• Persistent or worsening PSP beyond six months warrants reassessment for underlying venous reflux, not simply escalation of topical or device-based therapy.

Frequently Asked Questions

Is post-sclerotherapy pigmentation really preventable?

Most of it is, at least to a meaningful degree. Concentration is the single most controllable variable, and the difference between a 3% and a 73% incidence rate in the cited data is almost entirely explained by sclerosant strength. Combined with early coagulum evacuation, adequate compression, and sun protection, the six strategies in this article address the majority of modifiable risk.

How soon should I see patients back after treatment to check for retained coagulum?

The evidence supports a review at one to two weeks, at which point bulging, tender, or darkening areas can be identified and evacuated with a simple needle nick and gentle expression.

Is MPFF as good as sulodexide for preventing PSP?

The evidence is not equivalent. Sulodexide has been tested in a genuine randomised controlled trial. MPFF has supportive evidence from a large observational programme, which is a different and generally weaker evidence tier than a randomised trial, even though both showed a statistically significant reduction in PSP incidence.

What should I do if pigmentation is getting worse rather than better at six months?

This is the point at which you should reassess for a patent reticular feeder vein or truncal reflux, rather than simply moving to the next step of the topical or device-based algorithm. Ongoing reflux will keep depositing haemosiderin regardless of what is applied to the skin surface.

Where can I find detail on the topical agents and deferoxamine mesylate mentioned in the algorithm?

Part 1 of this series covers both in full, including the PSP-specific versus extrapolated evidence distinction for each topical agent, and the off-label status, evidence base, and safety profile of deferoxamine mesylate.

References

1. Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy: etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19-29. PMID: 7600016. https://pubmed.ncbi.nlm.nih.gov/7600016/

2. Bossart S, Daneluzzi C, Cazzaniga S, Ramelet AA, Uthoff H, Seyed Jafari SM, et al. Skin hyperpigmentation after sclerotherapy with polidocanol: a systematic review. J Eur Acad Dermatol Venereol. 2023;37:274-283. PMID: 36196455. https://pubmed.ncbi.nlm.nih.gov/36196455/

3. Goldman MP, Kaplan RP, Duffy DM. Postsclerotherapy hyperpigmentation: a histologic evaluation. J Dermatol Surg Oncol. 1987;13(5):547-550. PMID: 3571692. https://pubmed.ncbi.nlm.nih.gov/3571692/

4. Scultetus AH, Villavicencio JL, Kao TC, Gillespie DL, Ketron GD, Iafrati MD, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg. 2003;38:896-903. PMID: 14603191. https://pubmed.ncbi.nlm.nih.gov/14603191/

5. Kern P, Ramelet AA, Wutschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg. 2007;45(6):1212-1216. PMID: 17467226. https://pubmed.ncbi.nlm.nih.gov/17467226/

6. Nootheti PK, Cadag KM, Magpantay A, Goldman MP. Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins. Dermatol Surg. 2009;35:53-57. PMID: 19067733. https://pubmed.ncbi.nlm.nih.gov/19067733/

7. Gonzalez Ochoa AJ, Carrillo J, Manríquez D, Manrique F, Vazquez AN. Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. J Vasc Surg Venous Lymphat Disord. 2021;9(1):154-162. PMID: 32739509. https://pubmed.ncbi.nlm.nih.gov/32739509/

8. Bogachev VY, Boldin BV, Turkin PY. Administration of micronized purified flavonoid fraction during sclerotherapy of reticular veins and telangiectasias: results of the national, multicenter, observational program VEIN ACT PROLONGED-C1. Adv Ther. 2018;35(7):1001-1008. PMID: 29949043. https://pubmed.ncbi.nlm.nih.gov/29949043/

9. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg. 2004;30:367-372. PMID: 15008862. https://pubmed.ncbi.nlm.nih.gov/15008862/

10. Thibault PK, Wlodarczyk J. Correlation of serum ferritin levels and postsclerotherapy pigmentation: a prospective study. J Dermatol Surg Oncol. 1994;20:684-686. PMID: 7930015. https://pubmed.ncbi.nlm.nih.gov/7930015/

11. Scott C, Seiger E. Postsclerotherapy pigmentation. Is serum ferritin level an accurate indicator? Dermatol Surg. 1997;23(4):281-282. PMID: 9149795. https://pubmed.ncbi.nlm.nih.gov/9149795/

12. Jee SH, Lee SY, Chiu HC, Chang CC, Chen TJ. Effects of estrogen and estrogen receptor in normal human melanocytes. Biochem Biophys Res Commun. 1994;199:1407-1412. PMID: 8147884. https://pubmed.ncbi.nlm.nih.gov/8147884/

13. Mlosek RK, Wozniak W, Malinowska S, Migda B, Serafin-Krol M, Milek T. The removal of post-sclerotherapy pigmentation following sclerotherapy alone or in combination with crossectomy. Eur J Vasc Endovasc Surg. 2012;43(1):100-105. PMID: 22078293. https://pubmed.ncbi.nlm.nih.gov/22078293/

14. Alekseev N, Mishanina V. Combined laser therapy for post-sclerotherapy hyperpigmentation following Nicolau syndrome: a case report. Cureus. 2025;17:e82375. PMID: 40385807. https://pubmed.ncbi.nlm.nih.gov/40385807/

Gajraj H, Oliver R. Pigmentation after microsclerotherapy: causes, prevention and management. J Sclerother. 2026;2:000-000 (accepted for publication). DOI: 10.23736/S3103-4985.26.00021-8.

Part 1 of this series: "Topical Agents for Post-Sclerotherapy Pigmentation: What the Evidence Supports" (VeinCare Academy, July 2026).

About the Author

This educational article is written and regularly reviewed by Dr Haroun Gajraj, a GMC-registered vein specialist who has treated thousands of patients with vein disease and has trained many doctors and nurses in microsclerotherapy, radiofrequency thermocoagulation, and related cosmetic vein procedures. Dr Gajraj is the founder and board member of the British Association of Sclerotherapists. You can view his current GMC registration and independent patient reviews on iWantGreatCare for further information about his clinical background.

This article is intended for healthcare professionals and is based on current clinical guidelines, peer-reviewed research, and day-to-day practice experience. The information here is general education only and is not a substitute for individual clinical judgement, local protocols, or formal training. Clinicians remain responsible for assessing each patient, obtaining informed consent, explaining risks and alternatives, and working within the scope of their professional registration and regulatory guidance.

Subscribe

For regular updates get my weekly newsletter here

© VeinCare Academy | Dr. Haroun Gajraj | veincare.academy
This article is intended for qualified healthcare professionals. All clinical decisions should be based on individual patient assessment, primary medical literature and current professional guidelines.

*All references in this blog have been checked against publicly available sources (for example, PubMed and official guideline websites), but this is an educational blog post, not a peer-reviewed journal article. Minor discrepancies in author lists, page numbers or indexing details may remain, and readers should always refer to the original publications and current clinical guidelines before making clinical decisions.